RxDoctor Payments Data

Brian Kwong, DO

Vascular Surgery · Richmond, INNPI 1538511506

Payments from drug & device makers

What this record shows

It is spread thinly across 24 manufacturers, the largest accounting for just 20.6%. Reporting peaked in 2023 at $8,508 and has fallen 60.0% since, to $3,403 in 2025.

$12,675in general payments, 2019–2025

Across 123 payments — averaging $103.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$3K
  • Medtronic$3K
  • Inari Medical, Inc.$2K
  • Bard Peripheral Vascular, Inc.$1K
  • Silk Road Medical, Inc.$1K
  • Endologix LLC$766
  • plus $3K from 18 others

What the payments were for

  • Travel & lodging$6,49951%
  • Food & beverage$6,17649%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,675 in reported general payments places this provider in the 75th percentile of 71 vascular surgery providers in Indiana.

See all vascular surgery providers in Indiana

Medicare billing

Part B allowed, 2024
$110,806
Medicare patients
577
Services billed
1,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban22$19,281
EliquisApixaban19$11,324
ClopidogrelClopidogrel Bisulfate52$239
Cilostazol16$148

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$20$19,28122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 71 vascular surgery providers in Indiana.

Other vascular surgery in Richmond

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →